Pécsi Tudományegyetem
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 4 name spellings.
2
Ending by 2030
Sep 2029
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 3 fees due Jan 2 to 23, 2027 · next Jan 2
- 1 fee due Mar 8, 2027The maintenance fee for Pulse excited THz waveguide source based on optical rectification (US 9,128,349) comes due Mar 8, 2027. Unpaid by Sep 8, 2027, it lapses early.
- 1 fee due Apr 6, 2027The maintenance fee for Lung tissue model (US 9,151,744) comes due Apr 6, 2027. Unpaid by Oct 6, 2027, it lapses early.
- 1 fee due May 19, 2027The maintenance fee for Method to generate terahertz radiation and terahertz radiation source (US 10,481,468) comes due May 19, 2027. Unpaid by Nov 19, 2027, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,536,210 | Compounds for inhibiting semicarbazide-sensitive amine oxidase (SSAO)/vascular adhesion protein-1 (VAP-1) and uses thereof for treatment and prevention of diseases In force · USPTO record | In force | USPTO record | |
| US 9,151,744 | Lung tissue model In force · USPTO record | In force | USPTO record | |
| US 9,128,349 | Pulse excited THz waveguide source based on optical rectification In force · USPTO record | In force | USPTO record | |
| US 10,344,032 | Agents for treating neurogenic inflammation and neuropathic hyperalgesia related disorders In force · USPTO record | In force | USPTO record | |
| US 9,790,193 | Semicarbazide-sensitive amine oxidase inhibitors for use as analgesics in traumatic neuropathy and neurogenic inflammation In force · USPTO record | In force | USPTO record | |
| US 10,338,043 | P-nitrophenole-formaldehyde polycondensate for measurement, method of production and use In force · USPTO record | In force | USPTO record | |
| US 10,859,567 | Viability assessment of in vitro cultured human embryos from the culture medium In force · USPTO record | In force | USPTO record | |
| US 10,359,687 | Method to generate terahertz radiation and terahertz radiation source In force · USPTO record | In force | USPTO record | |
| US 9,884,040 | Desethylamiodarone for use in cancer treatment In force · USPTO record | In force | USPTO record | |
| US 10,699,446 | Process and measuring system for data acquisition and processing in soft-tomography studies In force · USPTO record | In force | USPTO record |
Also on record, not counted in the 16: 3 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
1 pending · 2 no status recorded